MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
short-term investments
$422,206K
Proceeds from issuance of
common stock through...
$81,259K
Net cash provided by
(used in) investing...
$91,338K
Net cash provided by
financing activities
$81,218K
Canceled cashflow
$330,868K
Canceled cashflow
$41K
Net increase
(decrease) in cash and cash...
$41,037K
Canceled cashflow
$131,519K
Purchases of short-term
investments
$323,938K
Purchases of property,
plant and equipment
$5,270K
Acquisition of licenses and
other assets, net
$1,660K
Accrued liabilities and
other current...
$84,148K
Stock-based compensation
expense
$31,146K
Contracts receivable
-$27,972K
Non-cash interest
related to sale of future...
$17,799K
Accrued compensation
$10,455K
Depreciation
$2,255K
Amortization of debt issuance
costs
$1,652K
Amortization of right-of-use
operating lease assets
$1,626K
Amortization of other assets
$621K
Income taxes
$20K
Principal payments on
mortgage debt
$41K
Net cash used in
operating activities
-$131,437K
Effects of exchange
rates on cash
-$82K
Canceled cashflow
$177,694K
Revenue
$156,721K
Other segment items
-$428K
Net loss
-$128,606K
Other current and
long-term assets
$100,953K
Canceled cashflow
$157,149K
Loss (gain) on
investments, net
$29,908K
Deferred contract
revenue
-$16,113K
Non-cash royalty revenue
related to sale of...
$13,584K
Accounts payable
-$8,807K
Amortization of discount on
investments, net
$5,085K
Non-cash losses related
to other assets
-$3,940K
Inventories
$2,135K
Drug development
$120,828K
Selling, general and
administrative
$86,565K
Drug discovery
$28,412K
R&d support
$23,093K
Manufacturing and development
chemistry
$15,790K
Medical affairs
$8,874K
Cost of sales
$2,193K
Back
Back
Cash Flow
source: myfinsight.com
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)